Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Deloitte
Citi
Accenture
McKesson
Mallinckrodt
Farmers Insurance
Fuji
Dow

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,664,231

« Back to Dashboard

Which drugs does patent 8,664,231 protect, and when does it expire?

Patent 8,664,231 protects RASUVO and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.
Summary for Patent: 8,664,231
Title:Concentrated methotrexate solutions
Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.
Inventor(s): Will; Heiner (Hamburg, DE)
Assignee: Medac Gesellschaft fuer Klinische Spezialpraepararate mbH (Wedel, DE)
Application Number:12/374,528
Patent Claim Types:
see list of patent claims
Use; Formulation; Device; Dosage form;

Drugs Protected by US Patent 8,664,231

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-001 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-002 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-003 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-004 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,664,231

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2006 033 837Jul 21, 2006
PCT Information
PCT FiledJuly 20, 2007PCT Application Number:PCT/EP2007/006491
PCT Publication Date:January 24, 2008PCT Publication Number: WO2008/009476

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Fish and Richardson
Moodys
Farmers Insurance
US Department of Justice
Federal Trade Commission
Queensland Health
Dow
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.